» Articles » PMID: 7738625

Prognostic Factors for Survival in Advanced Non-small-cell Lung Cancer: Univariate and Multivariate Analyses Including Recursive Partitioning and Amalgamation Algorithms in 1,052 Patients. The European Lung Cancer Working Party

Overview
Journal J Clin Oncol
Specialty Oncology
Date 1995 May 1
PMID 7738625
Citations 106
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: This study attempted to determine the prognostic value for survival of various pretreatment characteristics in patients with nonresectable non-small-cell lung cancer in the context of more than 10 years of experience of a European Cooperative Group.

Patients And Methods: We included in the analysis all eligible patients (N = 1,052) with advanced non-small-cell lung cancer registered onto one of seven trials conducted by the European Lung Cancer Working Party (ELCWP) during one decade. The patients were treated by chemotherapy regimens based on platinum derivatives. We prospectively collected 23 variables and analyzed them by univariate and multivariate methods.

Results: The global estimated median survival time was 29 weeks, with a 95% confidence interval of 27 to 30 weeks. After univariate analysis, we applied two multivariate statistical techniques. In a Cox regression model, the selected explanatory variables were disease extent, Karnofsky performance status, WBC and neutrophil counts, metastatic involvement of skin, serum calcium level, age, and sex. These results were confirmed by application of recursive partitioning and amalgamation algorithms (RECPAM), which led to classification of the patients into four homogeneous subgroups.

Conclusion: We confirmed by our analysis the role of well-known independent prognostic factors for survival, but also identified the effect of the neutrophil count, rarely studied, with the use of two methods: a classical Cox regression model and a RECPAM analysis. The classification of patients into the four subgroups we obtained needs to be validated in other series.

Citing Articles

Prognostic Value of the Noble and Underwood Score in Patients with Non-Small Cell Lung Cancer Undergoing Surgical Resection.

An S, Eo W, Kim D, Lee S J Cancer. 2024; 15(19):6185-6195.

PMID: 39513125 PMC: 11540506. DOI: 10.7150/jca.101320.


Multivariate analysis of prognostic factors in patients with lung cancer.

Liu C, Ma M, Zhou X, Zhang Z, Guo Y Front Oncol. 2023; 13:1022862.

PMID: 36910626 PMC: 9993855. DOI: 10.3389/fonc.2023.1022862.


Co-Mutation Status Association with Clinical Outcomes in Patients with -Mutant Non-Small Cell Lung Cancer.

Le X, Molife C, Leusch M, Rizzo M, Peterson P, Caria N Cancers (Basel). 2022; 14(24).

PMID: 36551611 PMC: 9776757. DOI: 10.3390/cancers14246127.


Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040).

Fukui T, Sasaki J, Igawa S, Kada A, Saito T, Kogure Y BMC Cancer. 2022; 22(1):1314.

PMID: 36522630 PMC: 9753257. DOI: 10.1186/s12885-022-10409-6.


Elevated neutrophil-to-lymphocyte ratio (NLR) is associated with poorer progression-free survival in unresectable stage III NSCLC treated with consolidation durvalumab.

Nindra U, Shahnam A, Stevens S, Pal A, Nagrial A, Lee J Thorac Cancer. 2022; 13(21):3058-3062.

PMID: 36111516 PMC: 9626316. DOI: 10.1111/1759-7714.14646.